NEWSROOM

BSEM

BioStem Technologies to Present at the 14th Annual LD Micro Invitational Conference

BioStem Technologies to Present at the 14th Annual LD Micro Invitational Conference

BioStem CEO, Jason Matuszewski, will present on Tuesday, April 9, 2024, at 12:30 pm ET POMPANO BEACH, FLORIDA, April 2, 2024—BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, today announced that it will present at the 14th Annual LD Micro Invitational Conference at the Sofitel New York on April 8-9, 2024. BioStem’s Chief Executive Officer, Jason...

read more
BioStem Technologies to Present at the 14th Annual LD Micro Invitational Conference

BioStem Technologies Reports Fourth Quarter Revenue of $11.5 Million, 14-Fold YoY Increase

-Project Continued Growth from Sales of AmnioWrap2®- -Financial Results Conference Call and Webcast on Monday, April 1, 2024 at 4:30 pm EDT- POMPANO BEACH, FLORIDA, April 1, 2024—BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics, today reported financial results for the fourth quarter and twelve months ended December 31, 2023. Jason Matuszewski, CEO of BioStem,...

read more
BioStem Technologies to Present at the 14th Annual LD Micro Invitational Conference

BioStem Technologies to Report Fourth Quarter 2023 Financial Results on Monday, April 01, 2024

Conference Call on Monday, April 1st, at 4:30 pm ET POMPANO BEACH, FLORIDA, March 21, 2024 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, announced today that it plans to release its fourth quarter 2023 financial results post-market Monday, April 01, 2024. BioStem will host a conference call and webcast at 4:30 pm ET on Monday, April 01, 2024....

read more
PRISM MarketView Spotlights BioStem Technologies in the Expanding Wound Care Market

PRISM MarketView Spotlights BioStem Technologies in the Expanding Wound Care Market

New York, N.Y. February 26, 2024 - PRISM MarketView announces the release of an insightful interview with BioStem Technologies' (OTC: BSEM) CEO, Jason Matuszewski, discussing the company's strategic focus on revolutionizing the wound care market through innovative regenerative medicine solutions. BioStem Technologies, a frontrunner in regenerative medicine, is dedicated to leveraging the healing properties of placental-derived allografts to enhance wound care. The company stands out for its...

read more
BioStem Technologies to Present at the 14th Annual LD Micro Invitational Conference

Amniowrap2™ Product Launch Leads Year of Highlights for BioStem Technologies

BioStem provides a business update and highlights recent accomplishments Preliminary fourth quarter net revenues of $11.5 million and full year 2023 net revenues of $16.7 million National Pricing for Amniowrap2™ effective January 1st in all 50 states and territories POMPANO BEACH, FLORIDA, January 30, 2024 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived allografts for advanced...

read more
BioStem Technologies to Present at the 14th Annual LD Micro Invitational Conference

BioStem Technologies Appoints Proven Life Science Sales Leader Shawn McCarrey to Chief Commercial Officer Role

Mr. McCarrey brings a strong track record of success and deep experience in regenerative medicine markets POMPANO BEACH, FLORIDA, January 11, 2024 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, today announces it has appointed a proven life science sales leader, Mr. Shawn McCarrey, as Chief Commercial Officer. BioStem Technologies CEO, Jason...

read more
BioStem Technologies Appoints Executive Leader Patrick Daly to Board of Directors

BioStem Technologies Appoints Executive Leader Patrick Daly to Board of Directors

POMPANO BEACH, FLORIDA, December 19, 2023 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, today announces it has appointed Mr. Patrick Daly to its Board of Directors. Mr. Daly is an award-winning executive leader with a strong track record of success in operations, strategy, sales, marketing, fundraising, and partnership-building. BioStem...

read more
Center for Medicare Services Established National Pricing of AmnioWrap2 (TM) in All MAC Regions

Center for Medicare Services Established National Pricing of AmnioWrap2 (TM) in All MAC Regions

Pricing Provides AmnioWrap2TM Reimbursement in All MAC Regions POMPANO BEACH, FLORIDA, December 14, 2023 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, announced that the Center for Medicare Services (CMS) has established national pricing for its product, AmnioWrap2TM, in all Medicare Administrative Contractors (MAC) regions. This pricing...

read more
Center for Medicare Services Established National Pricing of AmnioWrap2 (TM) in All MAC Regions

BioStem Technologies Bolsters Leadership with Appointment of Thomas Dugan to Board of Directors

POMPANO BEACH, FLORIDA, December 13, 2023 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, today announces the appointment of Mr. Thomas J. Dugan to the position of Chairman of the Board. Mr. Dugan brings a wealth of experience to BioStem, with proven, hands-on expertise as a senior executive who has transformed businesses, established new...

read more
BioStem Technologies Reports Third Quarter 2023 Operating and Financial Results

BioStem Technologies Reports Third Quarter 2023 Operating and Financial Results

Company to Host a Conference Call and Webcast on November 14, 2023, at 10:30 am EDT POMPANO BEACH, FLORIDA, November 13, 2023 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics, today reported financial results for the quarter ended September 30, 2023. Jason Matuszewski, Chief Executive Officer of BioStem Technologies Inc. said, “2023 has been a remarkable year of growth...

read more
BioStem Technologies Awarded Q Code for VENDAJE AC® Line from Centers for Medicare and Medicaid Services

BioStem Technologies Awarded Q Code for VENDAJE AC® Line from Centers for Medicare and Medicaid Services

POMPANO BEACH, FLORIDA, November 8, 2023 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture and commercialization of placental-derived biologics for advanced wound care, today announced that the Centers for Medicare and Medicaid Services (CMS) has published a new Q code, Q4279 for VENDAJE AC® pursuant to its application for Healthcare Common Procedure Coding System (HCPCS) “Q” codes. The HCPCS code assigned for VENDAJE...

read more
BioStem Technologies Awarded Q Code for VENDAJE AC® Line from Centers for Medicare and Medicaid Services

BioStem Technologies to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023

POMPANO BEACH, FLORIDA, November 6, 2023 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, announced today that it plans to release its third quarter 2023 financial results pre-market on Tuesday, November 14, 2023. BioStem will host a conference call and webcast at 10:30am ET on Tuesday, November 14, 2023. The call will include a discussion of...

read more
BioStem Technologies Closes Oversubscribed $2M Private Placement

BioStem Technologies Closes Oversubscribed $2M Private Placement

POMPANO BEACH, FLORIDA, November 3, 2023 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, today announces that it has closed an oversubscribed private placement of common stock to accredited investors for an aggregate of 1,337,000 units (each, a “Unit”) at a price of $1.50 per Unit for gross proceeds of $2 million. Each Unit consists of one...

read more
BioStem Technologies Closes Oversubscribed $2M Private Placement

BioStem Technologies Announces Opening of First Clinical Site for Diabetic Foot Ulcer Study

Study to support differentiated efficacy of Vendaje® structural tissue allograft POMPANO BEACH, FLORIDA, October 24, 2023 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, today announced that the first site is now fully opened for its clinical trial, evaluating the Vendaje® tissue allograft in the treatment of diabetic foot ulcers (DFU). Jason...

read more
BioStem Technologies to Present at the Fall Foliage MicroCap Rodeo Conference

BioStem Technologies to Present at the Fall Foliage MicroCap Rodeo Conference

POMPANO BEACH, FLORIDA, October 18, 2023 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, will present at the 2023 virtual Fall Foliage MicroCap Rodeo Conference to be held from October 24th - 27th. Jason Matuszewski, Chief Executive Officer of BioStem, said, “BioStem has achieved a number of significant milestones in 2023, including the...

read more
BioStem Technologies to Present at the Fall Foliage MicroCap Rodeo Conference

BioStem Technologies to Highlight Core Advanced Wound Care Portfolio at SAWC Fall 2023 Conference

POMPANO BEACH, FLORIDA, October 17, 2023 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, today announced that it will highlight the advantages of its Vendaje® and AmnioWrap2TM portfolios to help patients with difficult to heal chronic wounds at the 2023 Symposium on Advanced Wound Care (SAWC) Fall Conference held November 3rd – 5th in Las...

read more
BioStem Technologies to Present at the Fall Foliage MicroCap Rodeo Conference

BioStem Technologies: CMS Decision a “Win For Patients”

POMPANO BEACH, FLORIDA, September 29, 2023 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, today hails a decision by the Centers for Medicare & Medicaid Services (CMS) as being in the best interests of patients. Three Medicare Administrative Contractors today announced a decision to withdraw the final local coverage determinations (LCDs)...

read more
BioStem Technologies to Present at the Fall Foliage MicroCap Rodeo Conference

 “We have already demonstrated scientifically that our process and product is exceptional.”Jason Matuszewski, Chief Executive OfficerSeptember 26, 2023BioStem Technologies (OTC: BSEM) has received Investigational Review Board (IRB) approval for a clinical study that will investigate the utilization and effects of its Vendaje Ⓡ wound care product in diabetic foot ulcers.“We have already demonstrated scientifically that our process and product is exceptional. This study will enhance...

read more
BioStem Technologies to Present at the Fall Foliage MicroCap Rodeo Conference

BioStem Technologies Takes on Diabetic Foot Ulcers with Innovative Wound Care Product

“We have already demonstrated scientifically that our process and product is exceptional.” Jason Matuszewski, Chief Executive Officer September 26, 2023 BioStem Technologies (OTC: BSEM) has received Investigational Review Board (IRB) approval for a clinical study that will investigate the utilization and effects of its Vendaje Ⓡ wound care product in diabetic foot ulcers. “We have already demonstrated scientifically that our process and product is exceptional. This study will enhance our...

read more
BioStem Technologies to Present at the Fall Foliage MicroCap Rodeo Conference

BioStem Receives IRB Approval for Clinical Study to Evaluate Vendaje® in Diabetic Foot Ulcers

POMPANO BEACH, FLORIDA, September 26, 2023 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, announced today  the approval of an Investigational Review Board (IRB) sanctioned clinical study. This study aims to investigate the utilization and effects of Vendaje in diabetic patients suffering from foot ulcers. “This is a landmark study for...

read more
BioStem Technologies to Present at the Fall Foliage MicroCap Rodeo Conference

BioStem Technologies Initiates Nationwide Launch of AmnioWrap2™ with Venture Medical

Leading wound market solutions provider will lead BioStem’s commercialization of AmnioWrap2™ AmnioWrap2 is a versatile allograft solution for wound applications POMPANO BEACH, FLORIDA, September 19, 2023 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placenta-derived biologics for advanced wound care, has entered an agreement with leading US wound market solutions provider, Venture Medical,...

read more
BioStem Technologies to Present at the Fall Foliage MicroCap Rodeo Conference

BioStem Technologies Engages PCG Advisory for Strategic Investor Relations

POMPANO BEACH, FLORIDA, September 18, 2023 - BioStem Technologies Inc. (OTC: BSEM), an innovator in the development, manufacture, and commercialization of allografts for regenerative therapies, has engaged PCG Advisory, Inc., a leading investor relations and digital strategies firm, to serve as an advisor for investor relations and strategic communications. PCG Advisory will work closely with BioStem’s senior management team to build upon the company’s investor relations outreach and deliver a...

read more

Categories

Loading
Translate »